Skip to main content

Table 3 Diagnostic performance of the three-gene methylation classifier in the training and testing set of samples (at fixed sensitivity of 85% in the training set)

From: Urine cell-based DNA methylation classifier for monitoring bladder cancer

  Training set Testing set
Overall
N samples 111 BC/57 C 173 R-PFBC/285 NR-PFBC
 AUC 0.874 0.741
 SN (%) 84.68 89.6
 SP (%) 68.42 30.53
 PPV (%) 83.93 43.91
 NPV (%) 69.64 82.86
Non-high-risk NMIBC
N samples 26 BC/57 C 61 R-PFBC/285 NR-PFBC
 SN (%) 73.08 88.52
 SP (%) 68.42 30.53
 PPV (%) 51.35 21.43
 NPV (%) 84.78 92.55
High-risk NMIBC
N samples 60 BC/57 C 112 R-PFBC/285 NR-PFBC
 SN (%) 86.67 90.18
 SP (%) 68.42 30.53
 PPV (%) 74.29 33.78
 NPV (%) 82.98 88.78
MIBC
N samples 25 BC/57C
 SN (%) 92
 SP (%) 68.42
 PPV (%) 56.1
 NPV (%) 95.12
Low-grade
N samples 47 BC/57 C 96 R-PFBC/285 NR-PFBC
 SN (%) 76.6 90.62
 SP (%) 68.42 30.53
 PPV (%) 66.67 30.53
 NPV (%) 78 90.62
High grade
N samples 64 BC/57 C 77 R-PFBC/285 NR-PFBC
 SN (%) 90.62 88.31
 SP (%) 68.42 30.53
 PPV (%) 76.32 25.56
 NPV (%) 86.67 90.62
  1. LG low-grade, HG high-grade, AUC area under the curve, MIBC muscle-invasive bladder cancer, NMIBC non-muscle invasive bladder cancer, NPV negative predictive value, PPV positive predictive value, SN sensitivity, SP specificity, BC bladder cancer, C control, R-PFBC recurrent patients in follow-up for bladder cancer, NR-PFBC non-recurrent patients in follow-up for bladder cancer.